Advertisement
Screener

Protagonist Therapeutics, Inc (PTGX) Increase (Decrease) in Contract with Customer, Liability

2.8 / 5 stars · 68/120 Roast Me

Protagonist Therapeutics, Inc Increase (Decrease) in Contract with Customer, Liability

Protagonist Therapeutics, Inc (PTGX) reported Increase (Decrease) in Contract with Customer, Liability of $109.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-05

  • Protagonist Therapeutics, Inc increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $3.38M.
  • Protagonist Therapeutics, Inc increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$3.27M.
  • Protagonist Therapeutics, Inc increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$7.44M.
  • Protagonist Therapeutics, Inc increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$3.08M.
  • Protagonist Therapeutics, Inc increase (decrease) in contract with customer, liability for fiscal 2025 was -$21.02M, a 168.76% decline from fiscal 2024.
  • Protagonist Therapeutics, Inc increase (decrease) in contract with customer, liability for fiscal 2024 was $30.57M.
  • Protagonist Therapeutics, Inc increase (decrease) in contract with customer, liability for fiscal 2022 was -$1.60M.
  • Protagonist Therapeutics, Inc increase (decrease) in contract with customer, liability for fiscal 2021 was -$12.88M.
Period endIncrease (Decrease) in Contract with Customer, Liability 3 monthIncrease (Decrease) in Contract with Customer, Liability 6 monthIncrease (Decrease) in Contract with Customer, Liability 9 monthIncrease (Decrease) in Contract with Customer, Liability 9 month as first filedIncrease (Decrease) in Contract with Customer, Liability 12 month
2026-06-30$3.38M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$109.00K
10-Q · filed 2026-08-05
-$7.33M
derived: sum of 3 quarters · filed 2026-08-05
-$10.40M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31-$3.27M
10-Q · filed 2026-05-05
-$10.71M
derived: sum of 2 quarters · filed 2026-05-05
-$13.78M
derived: sum of 3 quarters · filed 2026-05-05
-$18.79M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31-$7.44M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
-$10.51M
derived: sum of 2 quarters · filed 2026-02-25
-$15.52M
derived: sum of 3 quarters · filed 2026-08-05
-$21.02M
10-K · filed 2026-02-25
2025-09-30-$3.08M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$8.08M
derived: sum of 2 quarters · filed 2026-08-05
-$13.58M
10-Q · filed 2025-11-06
-$19.22M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30-$5.01M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
-$10.50M
10-Q · filed 2026-08-05
-$16.14M
derived: sum of 3 quarters · filed 2026-08-05
-$20.82M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31-$5.50M
10-Q · filed 2026-05-05
-$11.13M
derived: sum of 2 quarters · filed 2026-05-05
-$15.81M
derived: sum of 3 quarters · filed 2026-05-05
-$19.98M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31-$5.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
-$10.31M
derived: sum of 2 quarters · filed 2026-02-25
-$14.48M
derived: sum of 3 quarters · filed 2026-02-25
$30.57M
10-K · filed 2026-02-25
2024-09-30-$4.67M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$8.84M
derived: sum of 2 quarters · filed 2025-11-06
$36.20M
10-Q · filed 2025-11-06
2024-06-30-$4.17M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06
$40.88M
10-Q · filed 2025-08-06
2024-03-31$45.05M
10-Q · filed 2025-05-06
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21
$0.00
derived: sum of 2 quarters · filed 2025-02-21
-$768.00K
derived: sum of 3 quarters · filed 2025-02-21
-$1.60M
10-K · filed 2025-02-21
2022-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02
-$768.00K
derived: sum of 2 quarters · filed 2023-11-02
-$1.60M
10-Q · filed 2023-11-02
-$2.24M
derived: sum of 4 quarters · filed 2024-02-27
2022-06-30-$768.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03
-$1.60M
10-Q · filed 2023-08-03
-$2.24M
derived: sum of 3 quarters · filed 2024-02-27
-$2.01M
derived: sum of 4 quarters · filed 2024-02-27
2022-03-31-$833.00K
10-Q · filed 2023-05-04
-$1.47M
derived: sum of 2 quarters · filed 2024-02-27
-$1.24M
derived: sum of 3 quarters · filed 2024-02-27
-$5.00M
derived: sum of 4 quarters · filed 2024-02-27
2021-12-31-$640.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27
-$408.00K
derived: sum of 2 quarters · filed 2024-02-27
-$4.17M
derived: sum of 3 quarters · filed 2024-02-27
-$12.88M
10-K · filed 2024-02-27
2021-09-30$232.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
-$3.53M
derived: sum of 2 quarters · filed 2022-11-08
-$12.24M
10-Q · filed 2022-11-08
-$18.64M
derived: sum of 4 quarters · filed 2023-03-15
2021-06-30-$3.76M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
-$12.47M
10-Q · filed 2022-08-04
-$18.87M
derived: sum of 3 quarters · filed 2023-03-15
-$32.00M
derived: sum of 4 quarters · filed 2023-03-15
2021-03-31-$8.71M
10-Q · filed 2022-05-05
-$15.11M
derived: sum of 2 quarters · filed 2023-03-15
-$28.25M
derived: sum of 3 quarters · filed 2023-03-15
-$33.28M
derived: sum of 4 quarters · filed 2023-03-15
2020-12-31-$6.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15
-$19.54M
derived: sum of 2 quarters · filed 2023-03-15
-$24.57M
derived: sum of 3 quarters · filed 2023-03-15
-$27.05M
10-K · filed 2023-03-15
2020-09-30-$13.14M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03
-$18.17M
derived: sum of 2 quarters · filed 2021-11-03
-$20.65M
10-Q · filed 2021-11-03
$14.06M
derived: sum of 4 quarters · filed 2022-02-28
2020-06-30-$5.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04
-$7.52M
10-Q · filed 2021-08-04
$27.20M
derived: sum of 3 quarters · filed 2022-02-28
-$7.55M
derived: sum of 4 quarters · filed 2022-02-28
2020-03-31-$2.48M
10-Q · filed 2021-05-04
$32.23M
derived: sum of 2 quarters · filed 2022-02-28
-$2.52M
derived: sum of 3 quarters · filed 2022-02-28
$32.04M
derived: sum of 4 quarters · filed 2022-02-28
2019-12-31$34.72M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
-$37.00K
derived: sum of 2 quarters · filed 2022-02-28
$34.53M
derived: sum of 3 quarters · filed 2022-02-28
$33.31M
10-K · filed 2022-02-28
2019-09-30-$34.75M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04
-$187.00K
derived: sum of 2 quarters · filed 2020-11-04
-$1.41M
10-Q · filed 2020-11-04
$30.45M
10-Q · filed 2019-11-06
-$1.16M
derived: sum of 4 quarters · filed 2021-03-10
2019-06-30$34.57M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
$33.34M
10-Q · filed 2020-08-06
$33.60M
derived: sum of 3 quarters · filed 2021-03-10
$28.36M
derived: sum of 4 quarters · filed 2021-03-10
2019-03-31-$1.22M
10-Q · filed 2020-05-07
-$969.00K
derived: sum of 2 quarters · filed 2021-03-10
-$6.20M
derived: sum of 3 quarters · filed 2021-03-10
-$14.88M
derived: sum of 4 quarters · filed 2021-03-10
2018-12-31$253.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10
-$4.98M
derived: sum of 2 quarters · filed 2021-03-10
-$13.66M
derived: sum of 3 quarters · filed 2021-03-10
-$23.53M
10-K · filed 2021-03-10
2018-09-30-$5.23M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06
-$13.91M
derived: sum of 2 quarters · filed 2019-11-06
-$23.78M
10-Q · filed 2019-11-06
-$33.77M
derived: sum of 4 quarters · filed 2020-03-10
2018-06-30-$8.68M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07
-$18.55M
10-Q · filed 2019-08-07
-$28.54M
derived: sum of 3 quarters · filed 2020-03-10
2018-03-31-$9.87M
10-Q · filed 2019-05-08
-$19.86M
derived: sum of 2 quarters · filed 2020-03-10
2017-12-31-$9.99M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10
$31.75M
10-K · filed 2020-03-10
2017-09-30$41.74M
10-Q · filed 2018-11-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
TG THERAPEUTICS, INC. (TGTX)United States$8.805B19.05
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Alkermes plc. (ALKS)$6.844B132.74
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20